Logo do repositório
 
Publicação

Development and pre-clinical evaluation of a new HIV-1 vaccine concept

datacite.subject.fosCiências Médicas::Medicina Básicapt_PT
dc.contributor.advisorTaveira, Nuno, 1964-
dc.contributor.advisorPereira, J. Moniz, 1949-
dc.contributor.authorCalado, Rita
dc.date.accessioned2018-04-10T09:41:52Z
dc.date.available2019-01-22T01:30:16Z
dc.date.issued2018
dc.date.submitted2018
dc.descriptionTese de doutoramento, Farmácia (Microbiologia), Universidade de Lisboa, Faculdade de Farmácia, 2018pt_PT
dc.description.abstractNew immunogens that elicit the production of broadly neutralizing antibodies (bNAbs) are needed to prevent and control HIV-1 epidemic. However, their induction by vaccination is still a difficult task. Prime-boost immunization strategies combining poxvirus with envelope glycoproteins constitutes a promising approach for an HIV-1 preventive vaccine as they provide strong immune responses. Recently, bNAbs against HIV-2 were elicited in mice using a Vaccinia vector-prime C2V3C3 polypeptide boost vaccination strategy. Thus, the main goal of this thesis was to determine if a similar strategy would elicit the production of bNAbs against HIV-1. The general aims of this thesis were: obtain and examine HIV-1 samples derived from Angolan isolates as a paradigm of the ancestral viruses we intended to use in a new type of vaccine, express envelope genes from Angolan and Portuguese isolates in Vaccinia virus and produce the autologous C2V3C3 recombinant polypeptides, investigate the immunogenicity of these immunogens in mice and rabbits using different regimens and quantify the respective cellular immune responses. In chapter 2, three full-length genomes from Angolan patients were sequenced and analyzed in order to better understand the origin and dynamics of HIV-1 in Angola. A pure subtype J, a subtype J with a small uncertain region and the first H/U/CRF02_AG recombinant were identified. Overall, these results supported the extraordinary genetic diversity of HIV-1 and confirm the ancestral presence of this subtypes in Angola. In chapters 3, gp120 glycoproteins expressed in Vaccinia virus, soluble gp120 and C2V3C3 polypeptides derived from several HIV-1 isolates from Angola and Portugal (clades B, C, CRF02_AG and J) were produced and used as immunogens in mice and rabbits (chapter 4). CRF02_AG based immunogens were able to elicit bNAbs against several heterologous HIV-1 tier 2 viruses and V3 region was found to be one of the main target of this immunogen. Antibody responses were associated with adequate Tfh and Tfr responses indicating that this strategy targeted the cellular subsets required for the induction of an effective NAb response. In conclusion, the results obtained suggest that the novel CRF02_AG based immunogens and primeboost immunization strategy may be able to induce the type of response intended in a preventive HIV-1 vaccine.pt_PT
dc.description.provenanceSubmitted by Amelia Janeiro (ajaneiro@reitoria.ul.pt) on 2018-03-20T16:32:13Z No. of bitstreams: 1 ulsd731511_td_Rita_Calado.pdf: 5276561 bytes, checksum: 0c9df29b6b78284b629421a1bad7b140 (MD5)en
dc.description.provenanceMade available in DSpace on 2018-04-10T09:41:52Z (GMT). No. of bitstreams: 1 ulsd731511_td_Rita_Calado.pdf: 5276561 bytes, checksum: 0c9df29b6b78284b629421a1bad7b140 (MD5) Previous issue date: 2018en
dc.identifier.tid101375921pt_PT
dc.identifier.urihttp://hdl.handle.net/10451/32686
dc.language.isoengpt_PT
dc.relationDEVELOPMENT AND PRE-CLINICAL EVALUATION OF A NEW HIV-1 VACCINE CONCEPT
dc.subjectTeses de doutoramento - 2018pt_PT
dc.titleDevelopment and pre-clinical evaluation of a new HIV-1 vaccine conceptpt_PT
dc.typedoctoral thesis
dspace.entity.typePublication
oaire.awardTitleDEVELOPMENT AND PRE-CLINICAL EVALUATION OF A NEW HIV-1 VACCINE CONCEPT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F70715%2F2010/PT
person.familyNameAlmeida Calado
person.givenNameRita Diogo
person.identifier.ciencia-idAA18-62FA-B4B3
person.identifier.orcid0000-0002-2519-7917
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.contributor.authoremailrepositorio@reitoria.ulisboa.pt
rcaap.rightsembargoedAccesspt_PT
rcaap.typedoctoralThesispt_PT
relation.isAuthorOfPublicationbca88dd5-4b60-4441-93dd-eddfa6fa50ef
relation.isAuthorOfPublication.latestForDiscoverybca88dd5-4b60-4441-93dd-eddfa6fa50ef
relation.isProjectOfPublication620d35e7-a0c0-439d-a4cc-481cc103b68f
relation.isProjectOfPublication.latestForDiscovery620d35e7-a0c0-439d-a4cc-481cc103b68f
thesis.degree.nameDoutoramento em Farmáciapt_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
ulsd731511_td_Rita_Calado.pdf
Tamanho:
5.03 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções